Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (181-190 of 509) with videos related to

Pageof 51
Sort By:
Alimentary Pharmacology & Therapeutics|November 30, 2023
Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trialNina Løn, Sara Engel, Anders Damholt, et al.
Gastroenterology|April 10, 2019
Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist LiraglutideMartin L Kårhus, Andreas Brønden, Michael E Røder, et al.
Obesity Surgery|February 3, 2011
Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric bandingLotte Usinger, Katrine B Hansen, Viggo B Kristiansen, et al.
Diabetes, Obesity & Metabolism|December 17, 2011
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesityFilip K Knop, K Aaboe, T Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous GlucoseHenrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Regulatory Peptides|June 29, 2010
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetesMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
The British Journal of Dermatology|October 31, 2018
Glucose metabolism in patients with psoriasisN U Friis, N Hoffmann, M Gyldenløve, et al.
Diabetes|February 13, 2010
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering actionKristine J Hare, Tina Vilsbøll, Meena Asmar, et al.
Diabetes, Obesity & Metabolism|August 7, 2012
Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T alleleK Færch, K Pilgaard, F K Knop, et al.
The Journal of Endocrinology|March 10, 2025
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axisMiriam Longo, David S Mathiesen, Lærke S Gasbjerg, et al.
Pageof 51

Showing results (181-190 of 509) with videos related to

Sort By:
Pageof 51
Alimentary Pharmacology & Therapeutics|November 30, 2023
Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trialNina Løn, Sara Engel, Anders Damholt, et al.
Gastroenterology|April 10, 2019
Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist LiraglutideMartin L Kårhus, Andreas Brønden, Michael E Røder, et al.
Obesity Surgery|February 3, 2011
Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric bandingLotte Usinger, Katrine B Hansen, Viggo B Kristiansen, et al.
Diabetes, Obesity & Metabolism|December 17, 2011
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesityFilip K Knop, K Aaboe, T Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous GlucoseHenrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Regulatory Peptides|June 29, 2010
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetesMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
The British Journal of Dermatology|October 31, 2018
Glucose metabolism in patients with psoriasisN U Friis, N Hoffmann, M Gyldenløve, et al.
Diabetes|February 13, 2010
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering actionKristine J Hare, Tina Vilsbøll, Meena Asmar, et al.
Diabetes, Obesity & Metabolism|August 7, 2012
Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T alleleK Færch, K Pilgaard, F K Knop, et al.
The Journal of Endocrinology|March 10, 2025
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axisMiriam Longo, David S Mathiesen, Lærke S Gasbjerg, et al.
Pageof 51